BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Pancreas
,
Biofuel
,
Lovastatin
,
rs3825942
,
TGFB1
,
Response to oxidative stress
,
Leukemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
miR 133
Summary
General Info
Curated Studies
Most Correlated Studies
SCC25 oral cancer cells overexpressing MIR10b or MIR196
Endothelial TIVE and BJAB B cells overexpressing miR-155 and miR-K12-11
miR-206 and miR-124 expressing cells from Dicer mutant and wildtype embryos
Ovarian cancer SK-OV-3 cells overexpressing MIR378 mimic
Pulmonary gene expression changes in mice exposed to benzo(a)pyrene by oral gavage
Explore Curated Studies Results
Literature
Most Relevant Literature
Endurance training changes the expression of miR-1 and miR-133 and predicted genes in slow and fast …
MicroRNA-133 suppresses cell viability and migration of rheumatoid arthritis fibroblast-like synovio…
Expression and clinical significance of miR-1 and miR-133 in pre-diabetes.
MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells.
Serum miR-133 as a novel biomarker for predicting treatment response and survival in acute myeloid l…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Interest of Plasma microRNAs
Probiotics on Body Composition and Insulin Resistance in Patients With Obesity and Its Association W…
Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study
miRNA and Myokines in Patients With PAH
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ